Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (DE:VX1)
XETRA:VX1
RESEARCH TOOLSreports
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 11.02B | $ 9.87B | $ 8.93B | $ 7.57B | $ 6.21B |
| Gross Profit | $ 9.49B | $ 8.61B | $ 7.85B | $ 6.67B | $ 5.47B |
| Operating Income | $ -232.90M | $ 3.83B | $ 4.31B | $ 2.78B | $ 2.86B |
| EBITDA | $ 486.30M | $ 4.61B | $ 4.44B | $ 2.92B | $ 3.28B |
| Net Income | $ -535.60M | $ 3.62B | $ 3.32B | $ 2.34B | $ 2.71B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 6.12B | $ 11.22B | $ 10.78B | $ 7.52B | $ 6.66B |
| Total Assets | $ 22.53B | $ 22.73B | $ 18.15B | $ 13.43B | $ 11.75B |
| Total Debt | $ 1.75B | $ 808.40M | $ 899.70M | $ 967.40M | $ 931.90M |
| Net Debt | $ -2.82B | $ -9.56B | $ -9.60B | $ -5.83B | $ -5.06B |
| Total Liabilities | $ 6.12B | $ 5.15B | $ 4.24B | $ 3.33B | $ 3.06B |
| Stockholders' Equity | $ 16.41B | $ 17.58B | $ 13.91B | $ 10.10B | $ 8.69B |
| Cash Flow | |||||
| Free Cash Flow | $ -790.30M | $ 3.28B | $ 3.93B | $ 2.41B | $ 2.99B |
| Operating Cash Flow | $ -492.60M | $ 3.54B | $ 4.13B | $ 2.64B | $ 3.25B |
| Investing Cash Flow | $ -3.77B | $ -3.14B | $ -321.10M | $ -340.90M | $ 99.39M |
| Financing Cash Flow | $ -1.49B | $ -562.20M | $ -67.70M | $ -1.48B | $ -505.28M |